Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Express Scripts
Merck
Moodys
Mallinckrodt

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CINACALCET HYDROCHLORIDE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Cinacalcet Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00094484 Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis Completed Amgen Phase 3 2004-10-01 The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).
NCT00110890 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed Amgen Phase 4 2004-05-01 The purpose of this study is to evaluate the ability of a treatment strategy, that includes cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid hormone (PTH) compared with the standard of care.
NCT00113945 Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD) Completed Amgen Phase 2 2003-07-01 The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) in subjects with ESRD receiving hemodialysis, on bio-intact parathyroid hormone (biPTH), corrected serum calcium, serum phosphorus, and calcium phosphorus product.
NCT00113958 Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels Completed Amgen Phase 2 1969-12-31 The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI recommended targets in subjects with end stage renal disease (ESRD) receiving hemodialysis, on bio-intact parathyroid hormone, corrected serum calcium, serum phosphorus, and calcium phosphorus product.
NCT00117052 SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism Completed Amgen Phase 3 2004-09-01 The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.
NCT00195936 Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets Unknown status Children's Mercy Hospital Kansas City Phase 1 2005-06-01 This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion.
NCT00261950 Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease Completed Amgen Phase 2 2006-05-01 The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cinacalcet Hydrochloride

Condition Name

Condition Name for Cinacalcet Hydrochloride
Intervention Trials
Secondary Hyperparathyroidism 23
Chronic Kidney Disease 13
End Stage Renal Disease 6
Hyperparathyroidism, Secondary 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cinacalcet Hydrochloride
Intervention Trials
Hyperparathyroidism 44
Hyperparathyroidism, Secondary 32
Neoplasm Metastasis 26
Kidney Diseases 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cinacalcet Hydrochloride

Trials by Country

Trials by Country for Cinacalcet Hydrochloride
Location Trials
United States 159
Spain 22
France 17
Canada 11
Italy 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cinacalcet Hydrochloride
Location Trials
California 12
New York 12
Missouri 10
Texas 9
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cinacalcet Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Cinacalcet Hydrochloride
Clinical Trial Phase Trials
Phase 4 18
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cinacalcet Hydrochloride
Clinical Trial Phase Trials
Completed 35
Recruiting 6
Terminated 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cinacalcet Hydrochloride

Sponsor Name

Sponsor Name for Cinacalcet Hydrochloride
Sponsor Trials
Amgen 28
Kyowa Hakko Kirin Co., Ltd 2
Montefiore Medical Center 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cinacalcet Hydrochloride
Sponsor Trials
Industry 36
Other 35
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Mallinckrodt
Colorcon
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.